Midorikawa Y, Haque Q M, Nakazawa S
Suzuka University of Medical Science, Department of Public Health, School of Medicine, Mie University, Mie, Japan.
Chemotherapy. 1998 Nov-Dec;44(6):409-13. doi: 10.1159/000007152.
The effect of deoxyspergualin (DSG) on the K1 strain of human malarial parasite Plasmodium falciparum in vitro was studied to test a possible new antimalarial chemotherapy. Hypoxanthine labeled with tritium (3H) was used to assess macromolecular synthesis. The inhibitory effects of DSG on the parasite peaked after 72 h of incubation. Parasitemia without DSG treatment was 9%, whereas at a DSG concentration of more than 156 microg/ml it was less than 1%. The amount of [3H]hypoxanthine taken up decreased with increasing DSG concentration. DNA synthesis of malarial activity decreased with increasing DSG concentration. These findings provide more evidence for the effects of DSG on this malarial parasite. As in previous in vivo studies done with DSG, the in vitro findings showed that DSG may be a new antimalarial drug.
研究了去氧精胍菌素（DSG）对体外培养的人类疟原虫恶性疟原虫K1株的作用，以测试一种可能的新型抗疟化疗方法。用氚（3H）标记的次黄嘌呤来评估大分子合成。DSG对疟原虫的抑制作用在孵育72小时后达到峰值。未用DSG处理时的疟原虫血症为9%，而当DSG浓度超过156微克/毫升时，疟原虫血症低于1%。随着DSG浓度的增加，摄取的[3H]次黄嘌呤量减少。随着DSG浓度的增加，疟原虫活性的DNA合成减少。这些发现为DSG对这种疟原虫的作用提供了更多证据。正如之前对DSG进行的体内研究一样，体外研究结果表明DSG可能是一种新型抗疟药物。
